Zhina Sadeghi1,2, Justin Isariyawongse1,2, Michael Kavran2, Kenan Izgi2, Gabriela Marini2,3, Joseph Molter4, Firouz Daneshgari2, Chris A Flask4,5,6, Arnold Caplan7, Adonis Hijaz8,9. 1. Urology Institute, University Hospitals of Case Medical Center, Department of Urology, Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH, 44106, USA. 2. Department of Urology, Case Western Reserve University School of Medicine, Cleveland, OH, USA. 3. Laboratory of Experimental Research on Gynecology and Obstetrics, Department of Gynecology and Obstetrics, Botucatu Medical School, Botucatu, Brazil. 4. Department of Radiology, Case Western Reserve University, Cleveland, OH, USA. 5. Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA. 6. Department of Pediatrics, Case Western Reserve University, Cleveland, OH, USA. 7. Skeletal Research Center, Biology Department, Case Western Reserve University, Cleveland, OH, USA. 8. Urology Institute, University Hospitals of Case Medical Center, Department of Urology, Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH, 44106, USA. Adonis.Hijaz@UHhospitals.org. 9. Department of Urology, Case Western Reserve University School of Medicine, Cleveland, OH, USA. Adonis.Hijaz@UHhospitals.org.
Abstract
INTRODUCTION AND HYPOTHESIS: We evaluated the potential role of human mesenchymal stem cells (hMSCs) in improvement of urinary continence following birth-trauma injury. METHODS: Human MSCs were injected periurethrally or systemically into rats immediately after vaginal distention (VD) (n = 90). Control groups were non-VD (uninjured/untreated, n = 15), local or systemic saline (injection/control, n = 90), and dermofibroblast (cell therapy/control, n = 90). Leak-point pressure (LPP) was measured 4, 10, and 14 days later. Urethras were morphometrically evaluated. In another sets of VD and non-VD rats, the fate of periurethrally injected hMSC, biodistribution, and in vivo viability was studied using human Alu genomic repeat staining, PKH26 labeling, and luciferase-expression labeling, respectively. RESULTS: Saline- and dermofibroblast-treated control rats demonstrated lower LPP than non-VD controls at days 4 and 14 (P < 0.01). LPP after systemic hMSC and periurethral hMSC treatment were comparable with non-VD controls at 4, 10, and 14 days (P > 0.05). Local saline controls demonstrated extensive urethral tissue bleeding. The connective tissue area/urethral section area proportion and vascular density were higher in the local hMSC- versus the saline-treated group at 4 and 14 days, respectively. No positive Alu-stained nuclei were observed in urethras at 4, 10, and 14 days. PKH26-labelled cells were found in all urethras at 2 and 24 h. Bioluminescence study showed increased luciferase expression from day 0 to 1 following hMSC injection. CONCLUSIONS: Human MSCs restored the continence mechanism with an immediate and sustained effect in the VD model, while saline and dermofibroblast therapy did not. Human MSCs remained at the site of periurethral injection for <7 days. We hypothesize that periurethral hMSC treatment improves vascular, connective tissue, and hemorrhage status of urethral tissues after acute VD injury.
INTRODUCTION AND HYPOTHESIS: We evaluated the potential role of human mesenchymal stem cells (hMSCs) in improvement of urinary continence following birth-trauma injury. METHODS:Human MSCs were injected periurethrally or systemically into rats immediately after vaginal distention (VD) (n = 90). Control groups were non-VD (uninjured/untreated, n = 15), local or systemic saline (injection/control, n = 90), and dermofibroblast (cell therapy/control, n = 90). Leak-point pressure (LPP) was measured 4, 10, and 14 days later. Urethras were morphometrically evaluated. In another sets of VD and non-VD rats, the fate of periurethrally injected hMSC, biodistribution, and in vivo viability was studied using humanAlu genomic repeat staining, PKH26 labeling, and luciferase-expression labeling, respectively. RESULTS:Saline- and dermofibroblast-treated control rats demonstrated lower LPP than non-VD controls at days 4 and 14 (P < 0.01). LPP after systemic hMSC and periurethral hMSC treatment were comparable with non-VD controls at 4, 10, and 14 days (P > 0.05). Local saline controls demonstrated extensive urethral tissue bleeding. The connective tissue area/urethral section area proportion and vascular density were higher in the local hMSC- versus the saline-treated group at 4 and 14 days, respectively. No positive Alu-stained nuclei were observed in urethras at 4, 10, and 14 days. PKH26-labelled cells were found in all urethras at 2 and 24 h. Bioluminescence study showed increased luciferase expression from day 0 to 1 following hMSC injection. CONCLUSIONS:Human MSCs restored the continence mechanism with an immediate and sustained effect in the VD model, while saline and dermofibroblast therapy did not. Human MSCs remained at the site of periurethral injection for <7 days. We hypothesize that periurethral hMSC treatment improves vascular, connective tissue, and hemorrhage status of urethral tissues after acute VD injury.
Authors: Guiting Lin; Guifang Wang; Lia Banie; Hongxiu Ning; Alan W Shindel; Thomas M Fandel; Tom F Lue; Ching-Shwun Lin Journal: Cytotherapy Date: 2010 Impact factor: 5.414
Authors: Charuspong Dissaranan; Michelle A Cruz; Matthew J Kiedrowski; Brian M Balog; Bradley C Gill; Marc S Penn; Howard B Goldman; Margot S Damaser Journal: Cell Transplant Date: 2013-07-17 Impact factor: 4.064
Authors: Jalees Rehman; Dmitry Traktuev; Jingling Li; Stephanie Merfeld-Clauss; Constance J Temm-Grove; Jason E Bovenkerk; Carrie L Pell; Brian H Johnstone; Robert V Considine; Keith L March Journal: Circulation Date: 2004-03-01 Impact factor: 29.690
Authors: Adonis K Hijaz; Kerry O Grimberg; Mingfang Tao; Brian Schmotzer; Zhina Sadeghi; Yi-Hao Lin; Michael Kavran; Ahmet Ozer; Nan Xiao; Firouz Daneshgari Journal: Female Pelvic Med Reconstr Surg Date: 2013 Nov-Dec Impact factor: 2.091
Authors: Hadley M Wood; Mei Kuang; Lynn Woo; Adonis Hijaz; Robert S Butler; Marc Penn; Raymond Rackley; Margot S Damaser Journal: J Urol Date: 2008-06-13 Impact factor: 7.450
Authors: Kristine Janssen; Dan Li Lin; Brett Hanzlicek; Kangli Deng; Brian M Balog; Carl H van der Vaart; Margot S Damaser Journal: Am J Physiol Renal Physiol Date: 2019-08-14
Authors: Zhina Sadeghi; Jonathan D Kenyon; Brian Richardson; Ahmad O Khalifa; Michael Cartwright; Britt Conroy; Arnold Caplan; Mark J Cameron; Adonis Hijaz Journal: Tissue Eng Part A Date: 2020-07-02 Impact factor: 3.845
Authors: Ahmad O Khalifa; Michael Kavran; Amr Mahran; Ilaha Isali; Juliana Woda; Chris A Flask; Marc S Penn; Adonis K Hijaz Journal: Int Urogynecol J Date: 2019-01-21 Impact factor: 2.894
Authors: Ofra Ben Menachem-Zidon; Michal Gropp; Etti Ben Shushan; Benjamin Reubinoff; David Shveiky Journal: PLoS One Date: 2019-06-13 Impact factor: 3.240